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Elicitation of broadly neutralizing antibodies remains
a long-standing goal of HIV vaccine research.
Although such antibodies can arise during HIV-1
infection, gaps in our knowledge of their germline,
pre-immune precursor forms, as well as on their
interaction with viral Env, limit our ability to elicit
them through vaccination. Studies of broadly
neutralizing antibodies from the VRC01-class pro-
vide insight into progenitor B cell receptors (BCRs)
that could develop into this class of antibodies.
Here, we employed high-throughput heavy chain var-
iable region (VH)/light chain variable region (VL) deep
sequencing, combined with biophysical, structural,
and modeling antibody analyses, to interrogate
circulating potential VRC01-progenitor BCRs in
healthy individuals. Our study reveals that not all hu-
mans are equally predisposed to generate VRC01-
class antibodies, not all predicted progenitor
VRC01-expressing B cells can bind to Env, and the
CDRH3 region of germline VRC01 antibodies influ-
ence their ability to recognize HIV-1. These findings
will be critical to the design of optimized immuno-
gens that should consider CDRH3 interactions.INTRODUCTION
VRC01-class antibodies target conserved elements of the CD4-
binding site (CD4-BS) of the HIV envelope glycoprotein (Env) and
potently neutralize diverse HIV-1 viruses (broadly neutralizing
antibodies [bNAbs]) (Scheid et al., 2011; Wu et al., 2010, 2011).
They protect animals from experimental HIV-1- or SHIV-chal-
lenge (Balazs et al., 2014; Pietzsch et al., 2012; Shingai et al.,
2014) and can transiently reduce plasma viremia during chronic
HIV-1 infection (Caskey et al., 2015; Lynch et al., 2015a). Approx-1560 Cell Reports 17, 1560–1570, November 1, 2016 ª 2016 The Au
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nine HIV-1-infected subjects (Zhou et al., 2015). They are highly
mutated in both the variable and framework regions (Scheid
et al., 2011; Wu et al., 2011), but despite a high degree of amino
acid (AA) divergence, they adopt similar structures that allow
them to engage the CD4-BS in a similar manner (Scharf et al.,
2013; Scheid et al., 2011; Wu et al., 2011; Zhou et al., 2010,
2013, 2015). All known VRC01-class bNAbs are derived from a
single heavy chain variable region (VH)1-2 allele, VH1-2*02,
and from four light chain variable region (VL) genes, k1-33,
k3-20, k3-15, and l2-14. The light chains (LCs) associated with
VRC01-class antibodies, all have unusually short CDRL3 do-
mains (five amino acids) (Zhou et al., 2015). Although the
mutated VRC01-class antibodies recognize a wide range of re-
combinant Env proteins and potently neutralize diverse isolates
(Scheid et al., 2011;Wu et al., 2011), their inferred germline forms
do not display such properties (Hoot et al., 2013). Naturally circu-
lating viral Envs that bind the known inferred VRC01-class anti-
bodies have yet to be identified. The majority of the information
we currently have on the interaction of the germline precursors
of VRC01-class antibodies with the HIV-1 Env is derived from
studies employing two specially designed recombinant Env-
based proteins (eOD and 426c ‘‘core’’) and the inferred germline
forms of these antibodies (Jardine et al., 2013, 2016; McGuire
et al., 2013, 2016).
Structural comparisons of the unliganded and liganded forms
of the mutated (mu) and inferred germline (igl) antibodies re-
vealed that the iglAbs exhibit preformed antigen-binding confor-
mations that are similar to those of the muAbs (Scharf et al.,
2016). Three amino acids are critically important for the interac-
tion of VRC01-class antibodies with Env because of the key con-
tacts they make with specific elements of the CD4-BS: Trp50HC
contacts the conserved amino acid Asn280 in Loop D, Asn58HC
contacts the conserved amino acid Arg456HC in V5, and Arg71HC
contacts amino acid Asp368 in the CD4-BS (Scharf et al.,
2013, 2016; West et al., 2012; Zhou et al., 2010, 2013). These
three amino acids are present in the gene-encoded VH do-
mains and remain unaltered during the extensive somatic hyper-
mutation process that VRC01-class antibodies undergo tothor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Relative Frequencies of VH1-2*02-
Expressing IgM+ B Cells in HIV-1 Humans
Next generation deep-sequencing (MiSeq) was
used to identify unique HC sequences of circu-
lating IgM+ B cells.
(A) Percentages of VH1-2 and VH1-2*02 se-
quences from each of the nine donors examined
are shown. The numbers represent the percent
of VH1-2 sequences out of the total VH1 se-
quences per donor (left column) or the per-
centage of VH1-2 sequences derived from the
*02 allele (right column). (–) indicates that
VH1-2*02 sequences were not detected. The
data are representative from multiple (2–4)
sequencing library runs from each subject. The
data shown are representative of these replicate
experiments.
(B) The amino acid identity of the VH1-2 HC
sequences from all donors examined was com-
pared to the published germline sequences for
each of the five VH1-2 alleles. The average and the median percent identity of all VH1-2 sequences from all donors are shown.
(C) Distribution of CDRH3 amino acid lengths (percent of total HCs per donor) and percent of all CDRH3 sequences expressing Trp100BHC (irrespective of
CDRH3 length) for each donor are shown.acquire their broad and potent neutralizing activities. These three
amino acids are also present in the VH1-2 alleles *03 and *04 (but
not in alleles *01 and *05), and thus, in principle, VRC01-class
Abs can also be derived from these two alleles (West et al.,
2012). Presently, it is unknown why all known VRC01-class
bNAbs are derived from the *02 allele but not from the *03
or *04 alleles.
In addition to the VH-encoded part of the HC of VRC01-class
antibodies, the CDRH3 found in the muVRC01-class Abs con-
tacts both the outer and inner domains of gp120 and expands
the overall binding surface areas of both the mutated and in-
ferred germline antibody forms and Env (Diskin et al., 2011;
Scharf et al., 2013; Zhou et al., 2010). All known muVRC01-class
bNAbs have a Trp at position 100B (Trp100BHC), located pre-
cisely five amino acids prior to framework region 4 (FWR4).
Trp100BHC hydrogen bonds with Asn279 in Loop D of gp120
and its presence is necessary for the neutralizing activity of
VRC01-class antibodies (West et al., 2012). Due to its location,
it is presently unknown whether Trp100BHC is the result of
V-D-J recombination at the ‘‘germline antibody level’’ or if it is
the result of somatic hypermutation and B cell selection.
igl VRC01-class Abs express the CDRH3 found in the corre-
sponding mutated antibody forms (because CDRH3 cannot be
reverted with certainty because it represents the combined ef-
fects of random V-D-J recombination, N additions, deletions,
and somatic mutation). Thus, the features of CDRH3s present
in germline VRC01-class antibodies and how they influence the
interaction of these antibodies with Env are unknown. Possibly,
a wide range of diverse CDRH3s is associated with VH1-2*02
sequences, but only a subset is conducive to Env-binding
(e.g., those that express Trp100BHC).
Defining the true nature of the germline CDRH3 of VRC01 an-
tibodies will assist efforts to designmore optimal immunogens to
activate naive B cells that express the precursor BCRs of
VRC01-class antibodies. To address this topic, we employed
diverse, but complementary approaches, including next genera-
tion MiSeq VH/VL sequencing of the naive BCR repertoire ofHIV-1 negative humans, coupled to structural and modeling
methods.
RESULTS
Allelic Frequencies of VH1-2 Sequences from
Circulating IgM+ B Cells in Humans
Next generation Illumina MiSeq analysis of the VH and VL of
circulating IgM+ B cells was performed in nine HIV-1-uninfected
individuals. Multiple VH/VL libraries were constructed from each
individual and replicate (2–4) MiSeq sequencing was performed.
A total of 298,368 unique VH1 sequences were identified by bio-
informatics analysis. Depending on the subject, VH1-2 repre-
sented between 2% and 30% of VH1 sequences (Figure 1A).
In seven of nine subjects examined, allele *02 represented be-
tween 75% and 100% of the total VH1-2 sequences. Two re-
maining subjects, LIB55 and LIBA, exclusively expressed allele
*05 or allele *04, respectively. As discussed above, allele *04
may be suitable for the generation of VRC01 antibodies, but
allele *05 is not. As expected, the vast majority of VH sequences
(from the beginning of FW1 until the YYCAR sequence prior to
the beginning of the CDRH3 domain) were very similar to the ex-
pected germline V gene for each allele (Figure 1B).
The CDRH3 Domains
The CDRH3s of most VRC01-class bNAbs range from 11–18
amino acids in length (Zhou et al., 2015), although they can be
as long as 23 amino acids (Wu et al., 2015). CDRH3s longer
than 19 amino acids were the minority in all subjects examined
(Figures 1C and S1A).
CDRH3s with Trp100BHC in LIB55 were not observed (Figures
1C and S1B). Thus, HCs derived from the VH1-2 *05 allele not
only lack one of the three VH-encoded key amino acids required
for Env-binding (Trp50) (Diskin et al., 2011; Klein et al., 2013;
Scharf et al., 2013), they also lack Trp100BHC in the CDRH3
that plays a key role in the neutralizing activities of VRC01-class
antibodies. In the remaining subjects, the frequency of CDRH3sCell Reports 17, 1560–1570, November 1, 2016 1561
expressing Trp100BHC varied between 1.6% (LIB3) and 29.3%
(LIB5) (Figures 1C and S1B).
Light Chains: The Presence of Five Amino Acid-Long
CDRL3
A defining feature of VRC01-class bNAbs is the presence of LCs
with unusually short (five amino acid-long) CDRL3 region (Kwong
andMascola, 2012; Zhou et al., 2013, 2015). The particular angle
of approach of VRC01-class bNAbs, which differs from the angle
of approach of non-neutralizing CD4-BS Abs (Chen et al., 2009;
Lyumkis et al., 2013), requires such short CDRL3. Thus, the short
CDRL3 is presently believed to be present in the germline forms
of these BCRs (Zhou et al., 2013).
In these same nine subjects described above, we performed a
parallel deep sequencing analysis of their circulating LC se-
quences (V-J) to define the frequencies of light chains with five
amino acid-long CDRL3s (Figure S2). Our analysis is in agree-
ment with previous reports (He et al., 2014; West et al., 2012)
that five amino acid-long CDRL3s are extremely rare in the hu-
manB cell repertoire. Our results reveal, however, that five amino
acid-long CDRL3s are more abundant in the k than the l locus.
This could be the reason why only a very small fraction of known
VRC01-class bNAbs express lLC (Scheid et al., 2011; Wu et al.,
2011; Zhou et al., 2015).
Selection and Expression of Germline VH1-2 Sequences
To investigate how sequence variations in CDRH3s affect the
Env-recognition properties of germline VRC01-class antibodies,
we selected 83 VH1-2 sequences (from all nine subjects): 9 from
the *01, 33 from the *02, 11 from the *03, 18 from the*04, and 12
from the *05 alleles. The complete amino acid sequences of
these 83 HCs are presented in Figures S3A–S3F. The HCs
were co-expressed with the known germline LC of VRC01-class
antibodies (k3-20, k1-33, k 3-11, and l 2-14). Similar ap-
proaches were previously employed to investigate the Env-
binding properties of diverse anti-HIV antibodies, including
mature VRC01-class antibodies (Bonsignori et al., 2016; Wu
et al., 2015; Zhu et al., 2013). The CDRH3 amino acid sequences
of these HCs are shown in Figures S4A–S4D. Our selection
criteria for HCs sequences were as follows: wide range of
CDRH3 lengths, presence or absence of Trp100BHC, and iden-
tical or divergent sequences to iglVRC01 outside the CDRH3
region.
We first attempted to co-express each VH with the k3-20 glLC
(that is associated with most known VRC01-class antibodies)
(Scheid et al., 2011; Wu et al., 2011; Zhou et al., 2015) (Table
S1). Sixty-two HCs (74%) were expressed. We then attempted
to express the remaining 21 HCs with k3-11, k1-33, or l2-14.
An additional six HCs were expressed (four *04-derived HCs
were expressed when paired with l2-14, while one *02 and
one *03-derived HC were expressed when paired with either
k3-11 or l2-14). Overall, out of the 82HC evaluated, 67 (82%) ex-
pressed as IgG. In cases where IgG-expression did not occur,
we assume that this was the result of HC/LC incompatibility.
The 15 HCs that were unsuccessfully paired with LCs expressing
five amino acid-long CDRL3s, most likely cannot be naturally
paired with such LCs in vivo and are thus incompatible with
the generation of VRC01-class antibodies.1562 Cell Reports 17, 1560–1570, November 1, 2016Env-Binding Recognition of Expressed Antibodies
Despite the broad binding and neutralizing activities of the
mutated forms of VRC01-class antibodies (i.e., as isolated
from chronically infected subjects), their inferred germline forms
do not display measurable Env-binding and recombinant Envs
fail to activate B cells engineered to express the iglVRC01-class
B cell receptors (BCRs) (Hoot et al., 2013; Jardine et al., 2013;
McGuire et al., 2013). We previously discussed the modification
of a clade C-derived Env (426c) that binds known iglVRC01
class-antibodies (McGuire et al., 2016). Briefly, this Env consists
of the gp120 subunit with deletions of N and C termini, the first,
second, and third variable domains and eliminations of three
N-linked glycosylation sites: one in Loop D (N276) and two in
V5 (N460 and N463). For brevity, we refer to this construct as
‘‘426c degly-3 core gp120’’ here.
We first evaluated the antibodies for binding to the soluble
monomeric form of 426c degly-3 core gp120 (Figure 2A).
iglVRC01 was used as positive control and it was the only anti-
body that displayed reproducible binding. We next examined
binding of these antibodies to two multimeric forms of 426c
degly-3 core gp120: a Ferritin particle-based 24-meric form (Fig-
ure 2B) and a C4b-based 7-meric form (Figure 2C) (McGuire
et al., 2016). Ten antibodies (seven *02, one *03, and two *04)
bound the Ferritin-based Env and nine (six *02, one *03, and
two *04) bound the C4b-based Env (Table S2). The apparent af-
finities of these antibodies varied, with similar kon rates as
compared to iglVRC01, but faster koff rates (Table S3). None of
the *01- and *05-derived antibodies bound these multimeric
Env forms (Figure 2D), confirming that the design of 426c
degly-3 core gp120 is specific for the VH1-2 alleles that express
the key amino acids of VRC01-class antibodies.
When the V1, V2, and V3 domains of gp120 were re-intro-
duced, thus recreating the full gp120, but still lacking the three
NLGS in Loop D and V5), two Abs (02-K and 02-O) bound the
Ferritin-based Env (426c degly-3 gp120 Ferritin), and only one
Ab (02-K) bound the C4b-based particles (426c degly-3 gp120
C4b) (Table S2A). Thus, in most cases, the presence of the var-
iable domains of gp120 hinders the binding of these potential
germline VRC01-class antibodies. However, iglVRC01 did bind
even in the presence of V1, V2, and V3 (as long as the three
NLGS in Loop D and V5 were absent). Overall, the 426c degly-3
core gp120-binding properties of the potential germline anti-
bodies examined here resemble that of the igl form of the
VRC01-class antibody 3BNC60 (McGuire et al., 2016).
Differences between the Germline VRC01-Class
Antibodies that Bind Env and Those that Do Not
With the exception of two antibodies, all antibodies that bound
426c degly-3 core gp120 had a 12 amino acid-long CDRH3
(Table S2B). Antibody 02-K had eight amino acid-long CDRH3
while 02-O had 11 amino acid-long CDRH3. However, not every
antibody with 8–12 amino acid-long CDRH3 bound 426c modi-
fied core gp120 (Figures 2 and S4A–S4D; Table S2C).
With the exception of antibody 03-F, the antibodies that bound
the 426c modified core gp120 express a related CDRH3
sequence (DxGxxSxW) (Table S2B) and had a Trp100BHC.
Non-binding Abs did not express this exact sequence motif,
although some expressed the Ser and Trp, but lacked the Asp
Figure 2. Binding of Expressed Germline Antibodies Derived from All Five VH1-2 Alleles to the 426c degly-3 Core gp120
The complete amino acid sequences of each HC expressed as IgG are shown in Figure S3. Each antibody was tested for binding to the 426c degly-3 gp120 core:
(A) monomeric form, (B) Ferritin particles (24-mer), and (C) C4b particles (7-mer). The igl VRC01 IgG was included. Binding and non-binding antibodies are
indicated. For clarity, the absence of interaction of antibodies derived from alleles *01 and *05 are shown separately (D). Vertical dotted lines represent the start of
the dissociation phase.and Gly (Table S2C). None of the known muVRC01class anti-
bodies express this motif (Scheid et al., 2011; Wu et al., 2011).
The Amino Acid Sequence of Germline CDRH3s Alters
the Env-Recognition Properties of glVRC01 Antibodies
To investigate directly whether and how differences in CDRH3
affect Env-recognition properties of germline VRC01-class anti-
bodies, we focused on key sequences. First, we focused on
02-CB, because it has an identical amino acid sequence outside
the CDRH3 as iglVRC01, it has the same length (12 amino acids)
but different CDRH3 amino acid sequence than iglVRC01 (Fig-
ure 3A), and yet iglVRC01 binds better to 426c degly-3 core
than 02-CB does (Figures 3B, 3C, and S5A). We surmised that
the different Env-binding properties of these two antibodies
are due to differences in the amino acid sequences in the
CDRH3 domains. Second, we focused on 02-K and 02-J,
because these two antibodies have identical sequences outside
their CDRH3 domains and while their CDRH3s have the same
length (eight amino acids long), their sequences differ (Figure 4A)
and only 02-K binds 426c degly-3 core (Figure S5B). Third, we
focused on 02-CC, because its CDRH3 is two amino acids
shorter than that of 02-CB (discussed above) but the remaining
portion is identical, and the two amino acids are not expected
tomake contact with Env (based on the available structural infor-
mation), in contrast to 02-CB it does not bind the 426c modified
core gp120 (Figures 5 and S5C). The apparent binding affinities
of the antibodies and their mutated forms discussed below are
presented in Tables S3 and S4.
02-CB
There are ten amino acid differences between the iglVRC01 and
02-CB CDRH3 sequences (Figure 3A). We first focused on the
‘‘Asp-Tyr-Asn’’ (DYN) tripeptide present in iglVRC01, as it hasbeen shown to interact, along with Trp100BHC, with Env (both
with the inner and outer gp120 domains) (Zhou et al., 2010).
The corresponding sequence in *02-CB is ‘‘Ser-Ser-Gly’’
(SSG). We determined the structure of the unliganded 02-CB
Fab (Figure 6) at 2.75 A˚ resolution in space group C2 (Table
S5), which we then superimposed onto the known structure of
iglVRC01 bound to eOD-GT6 (Jardine et al., 2013) (PDB: 4PKJ)
and to the structure of NIH45-46 bound to 426c degly-3 core
gp120 (Scharf et al., 2016) (PDB: 5IGX). This comparison re-
vealed that the presence of SSG would result in the loss of one
salt bridge and a loss of hydrophobic interactions. Overall the to-
tal buried surface (BSA) area between the CDRH3 of VRC01 and
02-CB are different (110 A2 for igl VRC01 to 78 A2 for 02-CB). To
formally examine this point, we mutated SSG to DYN in the
02-CB background (Figures 3B and 3C). This modification
improved the binding ability of 02-CB, almost to the same level
as iglVRC01.
An additional difference between the two CDRH3 sequences
is the presence of residues ‘‘Asn97-Cys98’’ (NC) immediately
preceding the DYN tripeptide in iglVRC01; that sequence is
‘‘Trp97-Tyr98’’ (WY) in 02-CB. These amino acids do not interact
directly with gp120 (Zhou et al., 2010), but in the modeled inter-
actions, the buried surface area between Tyr98 and gp120 is
85 A2 (accounting for more than half the total BSA). When the
‘‘WY’’ was replaced by ‘‘NC’’ on 02-CB, it resulted in loss (in
the case of the C4b 7meric) or a reduction (in the case of the
Ferritin 24meric) in binding, indicating that Tyr98 most likely
plays a role in the interaction with gp120. Our unliganded model
suggests a potential interaction of Tyr98 with Arg476 and/or
Arg480, but this needs direct confirmation once the structure
of the 02-CB/426c degly-3 core gp120 complex becomes avail-
able. The superposition of the unliganded 02-CB structure to that
of iglVRC01 bound to eOD-GT6 (Figure 6) indicates a possibleCell Reports 17, 1560–1570, November 1, 2016 1563
Figure 3. The Role of the CDRH3 Sequence
on the Binding of Germline 02-CB Antibody
to Env
(A) The CDRH3 sequences of iglVRC01 and 02-CB
antibodies, as well as the reverting mutations
(highlighted in orange) introduced in the 02-CB
CDRH3 region are shown. Trp100BHC is high-
lighted in yellow. Residues that make direct con-
tact with Env are indicated by asterisks.
(B and C) Binding to the C4b particles (7-mer) (B)
and Ferritin particles (24-mer) (C) expressing 426c
degly-3 core gp120. Vertical dotted lines indicate
the start of the dissociation phases.clash between residue Tyr98 of 02-CB and Arg46 of eODGT6
(that is absent from the 426c degly-3 core gp120). This suggests
that germline VRC01-class antibodies will interact with these two
proteins slightly differently. The orientation of this Tyr in the
structure of free 02-CC (see below), which has a similar
sequence as 02-CB, although a shorter CDRH3, is different. In
the 02-CB case, there is a symmetry interaction in the crystal
that may stabilize Tyr98 in that particular orientation. When all
five positions were mutated (the WYSSG sequence was re-
placed by NCDYN on the background of 02-CB), the antibody
binding further increased (closer to iglVRC01) (Figures 3B and
3C), indicating that likely themutations are compensatory. These
results highlight the important involvement of the germline
CDRH3s of VRC01-class antibodies in Env-binding.
02-K and 02-J
The structure of the free 02-K Fab (Figure 6B) was solved at 2.3 A˚
in space group P22121 (Table S5) and shows the orientation of
the shorter CDRH3. Its superposition with the known structure
of the liganded igl VRC01 antibody (Figures 6B and 6C) reveals
that the main interaction of its CDRH3 domain with Env will likely
be through Trp100BHC (Figure 6). This is reminiscent to what was
reported recently for VRC01c-HuGL2, a germline VRC01-class
antibody isolated from an HIV-1- human using the eOD-GT8 pro-
tein as ‘‘bait’’ (Jardine et al., 2016). This antibody lacks
Trp100BHC, but has a Tyr99 that is responsible for all contacts
from the CDRH3 with gp120 (Figures 6B and 6C).
Interestingly, 02-J has an eight amino acid-long CDRH3,
which is the same length as 02-K and also expresses a1564 Cell Reports 17, 1560–1570, November 1, 20163
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T6Trp100BHC, but it does not bind 426c
degly-3 core gp120 (Figures 4B, 4C, and
S5B). Its sequence outside of CDR H3 is
identical to iglVRC01. A key difference be-
tween the CDRH3s of 02-J and 02-K is the
presence of a Pro in 02-J (that corre-
sponds to a Phe in 02-K and iglVRC01)
(Figure 4A). When this Pro was replaced
by Phe on the 02-J background, binding
was observed (Figures 4B, 4C, and
S5B). Conversely, when the Phe was re-
placed by a Pro on the background of
either 02-K or iglVRC01, binding was
lost (Figure S6). These results not only
confirm that the germline CDRHsequence influences the binding affinities of germline VRC0
class antibodies with Env, but also indicate that not eve
circulating B cells that expresses a ‘‘VRC01-class’’ BCR (i.e.
VH1-2*02 HC paired with a LC with five amino acid-lo
CDRL3) will be able to bind to and become activated by Env.
02-CC
02-CC and 02-CB differ in five amino acids in the VH1-2 doma
(outside the CDRH3 domains), two of which are in the CDRH
domain (Figure 5A), which has been shown to interact with E
(Zhou et al., 2010): 02-CC has a Gly-Gly-Asp at position (5
56) while 02-CB (and iglVRC01) has a Ser-Gly-Gly. Asp at po
tion 56 is expected to clash with gp120 residue 472 using t
eOD-GT6 as model for superposition (PDB: 4JPK) (Jardi
et al., 2013). The loop formed by residues 471–473 of gp1
adopt a different conformation in the structure with matu
VRC01 (PDB: 3NGB) (Zhou et al., 2010). Because we want
to investigate the role of CDRH3, we decided to replace G
Gly-Asp by Ser-Gly-Gly in 02-CC to match glVRC01 sequen
in that region of interactions with gp120. This change result
in 02-CC binding to 426c degly-3 core gp120 (Figures 5B, 5
and S5C), confirming that VH1-2-encoded contacts with gp1
are important (Zhou et al., 2010).
To understand the contribution of the CDRH3, the structure
02-CC Fab was solved (Figure 6B) to 1.8 A˚ in space group P
(Table S5). Interestingly, Trp100BHC side chain adopts a differe
orientation than that of glVRC01, 02-CB or 02-K in its unligand
conformation that could be due to the CDRH3 length. Supe
position to the structure of iglVRC01 bound to eOD-G
Figure 4. The Role of the CDRH3 Sequence
on the Binding of Germline 02-J Antibody
to Env
(A) The CDRH3 sequences of iglVRC01, 02-J, and
02-K antibodies. The reverting mutations are
highlighted in orange and Trp100BHC is highlighted
in yellow.
(B and C) Binding to C4b particles (7-mer) (B) and
Ferritin particles (24-mer) (C) expressing 426c
degly-3 core gp120 are shown. Vertical dotted
lines indicate the start of the dissociation phases.revealed that the modeled interactions with gp120 will be similar
to those of 02-CB (Figure 6C). However, because of the side
chain rotation of Trp100BHC, the hydrogen bonding with
Asn279 on Env is lost in that particular conformation, but the hy-
drophobic interactions appear to be unaffected. The different
side chain orientation of Trp100BHC does not appear to be
responsible for 02-CC lack of binding (due to residues in the
CDRH2 mentioned above). It is also possible that the side chain
rotamer will differ in the structure of the bound complex.
DISCUSSION
Broad HIV-1 neutralizing serum antibody activities become
detectable 1–3 years following infection and only in a subset of
infected subjects (Doria-Rose et al., 2010; Goo et al., 2014;
Gray et al., 2011; Hraber et al., 2014; Mikell et al., 2011; Pianta-
dosi et al., 2009; Sather et al., 2009; Simek et al., 2009; van Gils
et al., 2009). Elucidating the underlying mechanisms of bNAb
development during infection will guide more appropriate immu-
nogen design efforts and immunization schedules (Dosenovic
et al., 2015). In three well-documented cases, the initiation of
bNAb-production required the emergence of viral clones ex-of
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thCell Repopressing Env with particular features that
allowed them to engage the pre-immune
BCRs of particular bNAbs. A cascade of
viral Env evolutionary and BCR matura-
tion steps ensued that lead to the produc-
tion of specifically mutated antibodies
capable of neutralizing not just the autolo-
gous virus, but heterologous viruses as
well. In one case, the bNAb (CAP256-
VRC26) targeted the apex of the Env spike
(Doria-Rose et al., 2014). In the second
and third cases, two inter-dependent
CD4-BS lineages (CH103 and CH235)
evolved in the same subject (Bonsignori
et al., 2016; Gao et al., 2014; Liao et al.,
2013). bNAbs like CAP256, CH103, and
CH235 contact their respective epitopes
primarily through their CDRH3 domains
(Kwong and Mascola, 2012), which is the
more common way by which antibodies
recognize their targets.
Overall, however, the underlying mech-
anisms associated with the developmentmost other types of HIV-1 bNAbs are poorly understood.
is is the case for VRC01-class antibodies, which bind the
4-BS of Env in a manner that is different from that of
103-like antibodies (Zhou et al., 2015), display very broad
utralizing activities (Scheid et al., 2011; Wu et al., 2011), and
hibit impressive protective potential under experimental ani-
al viral-challenge settings (Shingai et al., 2014). Samples
m the early stages of infection from relevant HIV-1+ subjects
e unavailable for analysis (Lynch et al., 2015b; Wu et al.,
12, 2015), and, as a result, the features of the viral Env clones
at initiated the development of VRC01-class antibodies in
ese subjects remain unknown. In contrast to the CAP256
d CH103 cases mentioned above, a natural viral clone that
n bind the inferred VRC01-class antibodies is presently un-
ailable. That and the fact that the inferred germline forms of
C01-class antibodies do not bind a wide range of Envs, sug-
sts that viral clonal variants with specific Env features initiated
e process of VRC01-class antibody-production during infec-
n in a subset of HIV-1-infected subjects.
The 426c degly-3 core gp120 is one of two optimized recom-
nant Env-derived proteins capable of binding and activating
e inferred forms of several known VRC01-class antibodiesrts 17, 1560–1570, November 1, 2016 1565
Figure 5. The Role of the CDRH2 Sequence
on the Binding of Germline 02-CC Antibody
to Env
(A) The CDRH2 (top) and CDRH3 (bottom) se-
quences of iglVRC01, 02-CC, and 02-CB anti-
bodies are shown. The reverting mutations in the
CDRH2 region of 02-CC at position 54 and 56 are
highlighted in orange. Trp100BHC is highlighted in
yellow.
(B and C) Binding to C4b particles (7-mer) (B) and
Ferritin particles (24-mer) (C) expressing 426c
degly-3 core gp120 are shown. Vertical dotted
lines indicate the start of the dissociation phases.(Jardine et al., 2013, 2016; McGuire et al., 2013, 2016). Here, we
show that 426c degly-3 core gp120 binds to several germline
VH1-2*02 HCs paired with the germline LC of known VRC01 an-
tibodies. Our study highlights the previously underappreciated,
role the CDRH3 domains of glVRC01-class antibodies play dur-
ing the initial step in the development of VRC01-class broadly
neutralizing antibody responses. The CDRH3may be less impor-
tant in the context of the already mutated antibody, most likely
because global changes resulting from affinity maturation allow
the antibody to optimally engage Env. We have analyzed over
298,368 unique VH1-2*02 sequences and the closest match to
the known (mature) CDRH3 of VRC01 antibodies had 58%
identity. Based on our results and those published previously
(DeKosky et al., 2015; He et al., 2014; Jardine et al., 2016; Lin
et al., 2016), we expect that a small fraction of those sequences
(0.01%–1.3%) will be paired with LCs with five amino acid-
long CDRL3s to generate putative germline VRC01 class anti-
bodies (between 60 and 7,750 depending on the subject).1566 Cell Reports 17, 1560–1570, November 1, 2016of
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that the modified Env examined in this
study will engage 8%–10% of those
antibodies. Improving the ability of immu-
nogens to engage a broader range of
putative VRC01 precursor B cells, will
require extensive and unbiased (i.e., not
based on recognition to presently avail-
able recombinant Env proteins) isolation
and characterization of numerous germ-
line VRC01-class antibodies (i.e., VH1-
2*02,*03, or *04 HCs naturally paired
with LCs expressing five amino acid-
long CDRL3s), combined with computa-
tional and modeling analyses of thou-
sands of germline CDRH3s to identify
specific ‘‘CDRH3 structural clusters,’’
around which one can redesign the
presently available germline-binding im-
munogens. Most likely, each ‘‘CDRH3
structural cluster’’ will require a distinct
set of immunogen modifications.
Ninety percent of the potential germline
VRC01-class antibodies studied here that
bound 426c degly-3 core gp120 ex-
pressed Trp100BHC. In contrast, 30%bona fide germline VRC01-class antibodies isolated usi
eOD-GT8 as ‘‘bait’’ expressed Trp100BHC (Jardine et a
2016). The CDRH3s of all known VRC01-class bNAbs have
Trp100BHC, which hydrogen bonds with Asn/Asp279 in Loop
of gp120, but it also interacts with the LC to stabilize the antibo
structure (West et al., 2012). B cells that express germline BCR
containing Trp100BHCmay have advantages when encounteri
Env, over those that do not. Such BCRs may more rapid
develop into broadly neutralizing antibodies than the BCRs th
lack Trp100BHC (that will require additional maturation step
The presence of the inner gp120 domain on 426c degly-3 co
gp120 (that is absent from eOD-GT8) potentially selects f
germline BCRs that already express Trp100BHC. IGHJ2*01
the only known human J segment that encodes Trp100BH
and 42% of the CDRH3 sequences with a Trp100BHC we
derived from that allele (50%were derived from the J4*02 allel
J5*01 is the only other J allele that encodes a Trp, but not
position 100BHC. The presence of Trp100BHC in all the VH1
Figure 6. Structural Analysis of CDRH3 of Germline VRC01-Class Antibodies
(A) CDRH3 sequence alignment from matured VRC01 (muVRC01), chimeric antibodies 02-CB, 02-K, 02-CC, and recently isolated germline VRC01c-HuGL2
(Jardine et al., 2016). The residues that are known to interact with gp120 from previously-reported crystal structures (Jardine et al., 2013, 2016; Zhou et al., 2010)
are shown in red, while the residues that interact with gp120 based on modeling analysis performed here are underlined.
(B) Structures of unbound germline VRC01-class Fabs. Structures of each single chain variable fragment (Fv) are shown in ribbon representation with the CDRH3
residues shown in ‘‘sticks.’’ The superposition of five Fabs is shown on the far left panel.
(C) Structures of germline VRC01-class antibodies bound to eOD-GT6 or eOD-GT8 (in the case of VRC01c-HuGL2). Superposition of the bound antibodies is
shown in the far left panel. Ribbon representations of each germline antibody bound to eOD are shown separately with the residues in CDRH3 shown as sticks and
residues that interact with gp120 are labeled. The structures of 02-CB, 02-K, and 02-CC antibodies bound to eOD are modeled (shown in lighter shade of gray).
(D) Summary of residues in the CDRH3 of the germline antibodies that interact with gp120. Buried surface area (BSA) over 5 A2, and hydrogen bonds (H) or salt
bridges (S) are indicated. Analysis for modeled interactions is italicized.sequences analyzed here was significantly higher in the *02 allele
than the *03 or *04 alleles (all of which express the remaining
three key amino acids that make contact with the CD4-BS:
Trp50HC, Asn58HC, and Arg71HC). This observation may explain
why all known VRC01-class bNAbs are derived from the *02
than the *03 or *04 alleles (West et al., 2012).
The binding of most (but not all) germline antibodies examined
here was abrogated by the variable regions 1–3 on gp120. The
known, mutated VRC01-class antibodies efficiently bind full-
length Env in a way that is unaffected by the presence of these
variable regions (Lyumkis et al., 2013; Stewart-Jones et al.,
2016). The weaker binding affinities of germline antibodies, and
differences in the angles of approach of the mutated and germ-
line VRC01 antibodies (Scharf et al., 2016), combined with the
flexibility of the variable regions 1–3 on gp120, appears therefore
to more drastically impact the binding of germline than mutatedVRC01-class antibodies. When soluble but stabilized trimeric
Envs (Sanders et al., 2015) that can bind germline VRC01-class
antibodies become available, it would be informative to deter-
mine whether such constructs are recognized by the antibodies
examined here.
The identification of naturally occurring, or the specific design
of, Env proteins that can activate the germline precursors of
VRC01-class antibodies are central to our efforts to elicit such
antibodies by vaccination. Our study reveals, however, that not
all humans are equally predisposed to generate VRC01-class
bnAbs, either during infection or by immunization. This should
be considered when designing clinical trials to evaluate the
potential of immunogens to elicit broadly neutralizing antibody
responses. In cases where the *02 allele is not expressed, immu-
nogens that target non-VRC01 class antibodies should be
evaluated.Cell Reports 17, 1560–1570, November 1, 2016 1567
In summary, our study improves our understanding of an
important class of broadly neutralizing and protective anti-
bodies against HIV-1. We expect this information to positively
contribute to the eventual elicitation of such antibodies by
vaccination.
EXPERIMENTAL PROCEDURES
Sample Acquisition
Whole blood samples were obtained by venipuncture from nine human
subjects. All sample collection and research involving human subjects was
conducted under human subjects research protocol HS029 at the Center for
Infectious Disease Research. The research and methods outlined in HS029
were reviewed and approved by the Western Institutional Review Board prior
to the initiation of any research. Peripheral blood mononuclear cells (PBMCs)
were isolated fromwhole blood by Ficoll density gradient separation. After two
washes in RPMI containing 10% fetal bovine serum (FBS), PBMCswere slowly
frozen in FBS (Sigma) supplemented with 10% DMSO in Mr. Frosty (Thermo
Fisher Scientific) cryo-containers.
Cell Preparation
PBMCs fromHIV donors were briefly thawed at 37C, diluted 10-fold in RPMI,
and centrifuged for 10 min at 4003 g. Cells were washed once in PBS, centri-
fuged again, resuspended in the fluorescence-activated cell sorting (FACS)
buffer (PBS with 2% FBS) and enumerated using a Countess II FL cell counter
(Thermo Fisher Scientific). Cells were then resuspended in Buffer RLT
(QIAGEN) supplemented with BME and stored at 80C until RNA was
extracted.
Library Preparation for Illumina MiSeq
B cell libraries for Illumina MiSeq sequencing were prepared as follows. Total
RNAwas extracted from 5–10million PBMCs using the All Prep DNA/RNAMini
Kit (QIAGEN). cDNA synthesis was subsequently initiated using AB Bio-
systems High Capacity cDNA Reverse Transcription Kit according to the man-
ufacturer’s protocol. For PBMC cDNA synthesis, 0.25–0.5 mg of total RNA was
used.
Multiplex PCR was performed with 50 ng of cDNA as a template. A 10 mM
cocktail of primers corresponding to VH1, VH2, VH3, VH4, VH5, VH6, and
VH7 (PMID: 21764753) (Scheid et al., 2011) was used with a 10-mM IgM
30 primer in a 25-mL reaction containing AccuPrime PFX (Life Technologies).
Light chain sequences were amplified with previously described forward and
reverse primer sets (Wardemann et al., 2003). PCR conditions were performed
according to the manufacturer’s suggested protocol employing the following
reaction conditions: 95C for 5 min followed by 25–40 cycles with 95C for
20 s, 55C for 35 s, and 68C for 35 s. Subsequent to primary cycling, a
68C, 5 min final elongation was performed, followed by a holding cycle at
10C. Ampliconswere visualized on 1.2%Flash Gels (Lonza) in order to assess
quality.
Libraries of sufficient cleanliness and quality were then gel purified using
1.2% Lonza Flash Gel purification gels. Approximately 50 ng of purified library
was used as a template for indexing PCR reactions, using 0.3 mL of Nextera
indexing primers (Illumina) and Accumprime PFX polymerase (Life Technolo-
gies) in a volume of 25 ml. Cycling conditions are identical to those above
with the following exceptions: reactions were performed with an annealing
temperature of 52C and ten cycles were performed. Indexed libraries were
then precipitated, concentrated, and purified on 1.2% Flash Gels (Lonza). Pu-
rified libraries were quantitated by Qubit (Life Technologies) prior to being
combined and loaded onto the MiSeq (Illumina).
Statistical Analysis
Samples were analyzed with non-parametric, two-way ANOVA using
GraphPad Prism version 7 when indicated. Data are presented as the average
of triplicates with error bars representing mean values ± SD and are represen-
tative of multiple experiments. Any additional statistical analysis methods are
indicated in the corresponding methods.1568 Cell Reports 17, 1560–1570, November 1, 2016ACCESSION NUMBERS
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